Last reviewed · How we verify
NCT07056491: REST4 Registry
REST4-AAA Registry
trial testing mRNA level of REST4 in serum; in Abdominal Aortic Aneurysm in 70 participants. Not yet recruiting.
1 July 2031
Quick facts
| Lead sponsor | RenJi Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 70 |
| Start date | 1 July 2025 |
| Primary completion | 1 July 2031 |
| Estimated completion | 1 July 2031 |
| Sites | 1 location across China |
Drugs / interventions tested
- mRNA level of REST4 in serum;
Conditions studied
- Abdominal Aortic Aneurysm — all drugs for Abdominal Aortic Aneurysm →
Sponsor
RenJi Hospital
Who can join
18 and older, any sex, with Abdominal Aortic Aneurysm. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This prospective observational study aims to investigate whether serum REST4 concentration can serve as a quantitative indicator correlated with abdominal aortic aneurysm (AAA) diameter and a predictive biomarker for AAA progression and rupture risk. Emerging evidence suggests that REST4, a splice variant of the RE-1 Silencing Transcription Factor (REST), is upregulated in vascular smooth muscle cells during AAA pathogenesis and may be released into circulation via exosomes. The study will enroll patients with asymptomatic AAA (diameter between 39-49 mm) and measure baseline serum REST4 levels, analyzing their association with morphological severity (maximum aortic diameter) and clinical outcomes (aneurysm growth rate, rupture and related mortality) through a 5-year follow-up period.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07056491
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Abdominal Aortic Aneurysm
Currently open trials in the same condition.
- NCT07476196 — Poland-Italy Aortic Research Bridge Real World Registry · recruiting
- NCT07473102 — PET Imaging of MMP Activation in AAA: Clinical Component · EARLY_PHASE1 · recruiting
- NCT06451315 — REGISTRY on the Implementation of Artificial Intelligence in the Automatic Analysis of Vascular Network Segmentation · recruiting
- NCT06001918 — Nectero EAST System Clinical Study · Phase 2, PHASE3 · recruiting
- NCT06008613 — 3D Holographic Guidance, Navigation, and Control for Endovascular Aortic Repair · NA · active not recruiting
Other RenJi Hospital trials
Trials by the same sponsor.
- NCT07584733 — Biomarker-Enriched Kidney-Preserving Strategy With Disitamab Vedotin Plus Tislelizumab in HER2-Positive High-Risk Upper · Phase 2 · not yet recruiting
- NCT07537725 — EEG-TMS for Postoperative Delirium After Cardiac Surgery · NA · not yet recruiting
- NCT07527936 — A Study of BEN301 Injection in theTreatment of Autoimmune Diseases · EARLY_PHASE1 · not yet recruiting
- NCT07343076 — Efficacy of Immediate Versus Staged Complete Revascularization in Patients With NSTE-ACS and Multivessel Disease (FUTURE · NA · not yet recruiting
- NCT07449793 — Biochemical Response and Clinical Outcomes in Patients With PBC · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07056491 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by RenJi Hospital
- Last refreshed: 9 July 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07056491.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing